Skip to main
GPCR

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics Inc has demonstrated a positive trajectory following encouraging Phase 2 data and strategic interviews with Key Opinion Leaders, which have informed a bullish outlook and increased price targets from $60 to $140 per share. The company's differentiated approach to drug development, particularly the micro-titration method, is expected to enhance the therapeutic index of its drug candidates, positioning its oral agents as potential replacements for injectable therapies and addressing significant unmet medical needs within chronic disease management. Additionally, the anticipated results from upcoming Phase 1 studies and the commencement of Phase 3 trials could further solidify Structure's competitive edge in the biopharmaceutical market, enhancing its value proposition.

Bears say

Structure Therapeutics Inc faces considerable challenges regarding the adoption and efficacy of its oral therapeutics, particularly given the historical bioavailability issues associated with GLP-1 formulations, which limit their effectiveness compared to injectables. Additionally, the company encounters multiple downside risks, including potential underperformance in clinical studies for its lead product, aleniglipron, as well as increased competition within the oral incretin space and the risk of strategic partnerships diverting away from their offerings. Furthermore, the projected demand for obesity therapeutics underscores a significant supply-demand imbalance, emphasizing the urgent need for highly effective oral agents, which could put Structure Therapeutics at a competitive disadvantage in a rapidly evolving market.

GPCR has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Buy based on their latest research and market trends.

According to 12 analysts, GPCR has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.